Skip to main content

Table 2 Summary of circulating miRNA biomarkers identified through qRT-PCR profiling

From: Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling

  Step 1 Step 2 Step 3 Step 4  
Disease No.
Pa/Nor
Type Kit Method Normalizer No.
Pa/Nor
Marker Function Statistical
analysis
References
ovarian
cancer
9/4 S TR AB U44
U48
19/11 miR-21
miR-92
miR-93
Severity Mann-Whitney [27]
prostate
cancer
21/
N/A
S TR AB cel-miR-39 cel-miR-54 cel-miR-238 113/
N/A
miR-375 miR-141 Severity
Tissue
Limma analysis
ANOVA
[28]
colorectal
cancer
5/5 P Tz SBI U6 115/70 miR-17
-3p miR-92
Severity
Tissue
Prognosis
Mann-Whitney
Wilcoxon
the χ2 test
Kruskal-Wallis
ROC
[21]
HBV
infected
51/12 S mir AB U6 51/12 miR-122 Severity Mann-Whitney [29]
Crohn
disease
46/32 S mir AB miR-302a
miR-372
miR-302d
cel-miR-54
cel-miR-238
46/32 11 miRNAs* Severity Prognosis Mann-Whitney
Hierarchical- cluster
ROC
[30]
liver disease 5/2 S mir AB U6 112/24 miR-885-5p Comparison Mann-Whitney
Kruskal-Wallis
ROC
[24]
  1. HBV: hepatitis B virus; Pa: patients; Nor: normal; N/A: not available; S: serum; P: plasma; TR: Tri-Reagent BD (Molecular Research Center or Sigma); Tz: Trizol LS reagent (Invitrogen); mir: mirVana™ miRNA isolation kit (Ambion); AB: Megaplex™ Pools (Applied Biosystems); SBI: QuantiMir™ (System Biosciences); Severity: correlation of miRNAs expression level with disease severity; Prognosis: correlation of miRNAs expression level and the treatment of disease; Tissue: correlation of miRNAs expression level in serum with that in tissue; Comparison: comparison between newly identified miRNA biomarkers and conventional biomarkers; ROC: Receiver operating characteristic curve; ANOVA: Analysis of variance.
  2. *: miR-16, miR-195, miR-106a, miR-20a, miR-30e, miR-140, miR-484, miR-93, miR-192, miR-21, let-7b.